Intervention Review

Rosiglitazone for type 2 diabetes mellitus

  1. Bernd Richter1,*,
  2. Elizabeth Bandeira-Echtler1,
  3. Karla Bergerhoff1,
  4. Christine Clar2,
  5. Susanne H Ebrahim3

Editorial Group: Cochrane Metabolic and Endocrine Disorders Group

Published Online: 18 JUL 2007

Assessed as up-to-date: 29 APR 2007

DOI: 10.1002/14651858.CD006063.pub2


How to Cite

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006063. DOI: 10.1002/14651858.CD006063.pub2.

Author Information

  1. 1

    Universitaetsklinikum Duesseldorf, Heinrich-Heine University, Department of General Practice, Duesseldorf, Germany

  2. 2

    Cochrane Metabolic and Endocrine Disorders Group, Researcher in Systematic Reviews , Berlin, Germany

  3. 3

    Institute for Quality and Efficiency in Health Care, Cologne, Germany

*Bernd Richter, Department of General Practice, Universitaetsklinikum Duesseldorf, Heinrich-Heine University, PO Box 101007, Duesseldorf, 40001, Germany. richterb@uni-duesseldorf.de.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 18 JUL 2007

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Carl Asche, Joanne LaFleur, Christopher Conner, A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes, Clinical Therapeutics, 2011, 33, 1, 74

    CrossRef

  2. 2
    Ronen Loebstein, Marina Dushinat, Janet Vesterman-Landes, Barbara Silverman, Nurit Friedman, Itzhak Katzir, Daniel Kurnik, Yossef Lomnicky, Ehud Kokia, Hillel Halkin, Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes, The Journal of Clinical Pharmacology, 2011, 51, 2
  3. 3
    Cochrane Clinical Answers, 2011,

    CrossRef

  4. 4
    Cochrane Clinical Answers, 2011,

    CrossRef

  5. 5
    Sandeep A. Saha, Katherine R. Tuttle, Influence of Glycemic Control on the Development of Diabetic Cardiovascular and Kidney Disease, Cardiology Clinics, 2010, 28, 3, 497

    CrossRef

  6. You have free access to this content6
    Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, Campbell D, Nicholls K, Tong A, Mangos G, Stack A, MacIsaac RJ, Girgis S, Colagiuri R, Colagiuri S, Craig J, Prevention and management of chronic kidney disease in type 2 diabetes, Nephrology, 2010, 15,
  7. 7
    Sanjay Kaul, Ann F. Bolger, David Herrington, Robert P. Giugliano, Robert H. Eckel, Thiazolidinedione Drugs and Cardiovascular Risks, Journal of the American College of Cardiology, 2010, 55, 17, 1885

    CrossRef

  8. 8
    María D. Ballesteros-Pomar, Miguel León-Sanz, Nutrition in the metabolic syndrome: Pharmacological treatment, e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, 2008, 3, 3, e108

    CrossRef

  9. 9
    Colin Kenny, Rosiglitazone and the thiazolidinediones: A changing context, Primary Care Diabetes, 2007, 1, 4, 185

    CrossRef

  10. 10
    Maren Mayhew, Thiazolidinediones—the Ongoing Debate, The Journal for Nurse Practitioners, 2007, 3, 10, 722

    CrossRef

  11. 11
    Sinead Brophy, Helen Davies, Sopna Mannan, Huw Brunt, Rhys Williams, Interventions for latent autoimmune diabetes (LADA) in adults, The Cochrane Library,
  12. 12
    Bianca Hemmingsen, Lars H Lundstrøm, Christina Hemmingsen, Søren S Lund, Jørn Wetterslev, Christian Gluud, Allan Vaag, Thomas Almdal, Non-incretin insulin secretagogues for patients with type 2 diabetes mellitus, The Cochrane Library,
  13. 13
    Bianca Hemmingsen, Jeppe B Schroll, Søren S Lund, Jørn Wetterslev, Christian Gluud, Allan Vaag, David Peick Sonne, Lars H Lundstrøm, Thomas P Almdal, Sulphonylurea monotherapy for patients with type 2 diabetes mellitus, The Cochrane Library,
  14. 14
    Bianca Hemmingsen, Jeppe B Schroll, Søren S Lund, Jørn Wetterslev, Christian Gluud, Allan Vaag, David Peick Sonne, Lars H Lundstrøm, Thomas P Almdal, Sulphonylurea monotherapy for patients with type 2 diabetes mellitus, The Cochrane Library,
  15. 15
    Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas P Almdal, Jørn Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus, The Cochrane Library,
  16. 16
    Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Jørn Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus, The Cochrane Library,
  17. 17
    Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas Almdal, Christina Hemmingsen, Jørn Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus, The Cochrane Library,
  18. 18
    Bianca Hemmingsen, Søren S Lund, Christian Gluud, Allan Vaag, Thomas P Almdal, Jørn Wetterslev, Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus, The Cochrane Library,